Indonesia vs Lebanon: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Indonesia
69.0%
in 2025
Lebanon
67.0%
in 2025
Indonesia rank
133rd
Lebanon rank
135th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Indonesia
- Lebanon
How they compare
Indonesia currently reports 69.0% against 67.0% in Lebanon, a difference of 2.0%.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Lebanon ahead.
Indonesia ranks 133rd and Lebanon ranks 135th of 192 countries.
Lebanon has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Indonesia | Lebanon | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 0.3% | 24.6% | 24.3% | Lebanon |
| 2020s | 30.2% | 68.2% | 38.0% | Lebanon |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Indonesia or Lebanon?
- Indonesia, at 69.0% against 67.0% in Lebanon as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Indonesia and Lebanon?
- 2.0%, with Indonesia ahead.
- How many years of comparable data are there for Indonesia and Lebanon?
- 18 years are reported by both, from 2008 to 2025.
- How do Indonesia and Lebanon rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Indonesia ranks 133rd and Lebanon ranks 135th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.